Ivabradine was associated with lower risks of MACE, HFE, and all-cause mortality compared with digoxin in patients with HFrEF and chronic kidney disease.
Does ivabradine reduce MACE, HFE, and all-cause mortality in patients with HFrEF and CKD compared to digoxin?
In patients with HFrEF and CKD, ivabradine is associated with improved clinical outcomes and lower mortality compared to digoxin, offering a potentially safer heart-rate-lowering alternative.
Tasa de eventos absoluta: 0% vs 0%
In this large, real-world cohort of patients with HFrEF and CKD, ivabradine was associated with lower risks of MACE, HFE, and all-cause mortality compared with digoxin. Ivabradine may represent a safer and more effective heart-rate-lowering option for this high-risk population.
Wu et al. (Sat,) reported a other. Ivabradine was associated with lower risks of MACE, HFE, and all-cause mortality compared with digoxin in patients with HFrEF and chronic kidney disease.